Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency
Citations Over TimeTop 10% of 2018 papers
Abstract
We describe a novel, two-nanoparticle mRNA delivery system and show that it is highly effective as a means of intracellular enzyme replacement therapy (i-ERT) using a murine model of ornithine transcarbamylase deficiency (OTCD). Our Hybrid mRNA Technology delivery system (HMT) comprises an inert lipid nanoparticle that protects the mRNA from nucleases in the blood as it distributes to the liver and a polymer micelle that targets hepatocytes and triggers endosomal release of mRNA. This results in high-level synthesis of the desired protein specifically in the liver. HMT delivery of human OTC mRNA normalizes plasma ammonia and urinary orotic acid levels, and leads to a prolonged survival benefit in the murine OTCD model. HMT represents a unique, non-viral mRNA delivery method that allows multi-dose, systemic administration for treatment of single-gene inherited metabolic diseases.
Related Papers
- → Late‐onset ornithine transcarbamylase deficiency: a rare cause of recurrent abnormal behavior in adults(2020)14 cited
- → Ornithine Transcarbamylase Deficiency — A Cause of Bizarre Behavior in a Man(1986)64 cited
- → Prenatal Diagnosis of Ornithine Transcarbamylase Deficiency with Use of DNA Polymorphisms(1986)31 cited
- Prenatal diagnosis of ornithine transcarbamylase deficiency utilizing fetal liver biopsy.(1984)
- → Use of Immunocytochemical Analysis of a Duodenal Biopsy Specimen to Identify a Carrier of Ornithine Transcarbamylase Deficiency(1988)11 cited